Argipressin Acetate | CAS#113-79-1 | antidiuretic hormone

Argipressin Acetate
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326638

CAS#: 113-79-1 (free base).

Description: Argipressin is the predominant form of mammalian antidiuretic hormone. Argipressin is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked CYSTEINES at residues of 1 and 6. Arg-vasopressin is used to treat diabetes insipidus or to improve vasomotor tone and blood pressure.

Chemical Structure

Argipressin Acetate

CAS# 113-79-1 (free base).

Instruction

Theoretical Analysis

MedKoo Cat#: 326638
Name: Argipressin Acetate
CAS#: 113-79-1 (free base).
Chemical Formula: C48H69N15O14S2
Exact Mass: 0.00
Molecular Weight: 1,144.291
Elemental Analysis: C, 50.38; H, 6.08; N, 18.36; O, 19.57; S, 5.60

Price and Availability

Size	Price	Availability	Quantity
1g	USD 2950
2g	USD 5450
5g	USD 8650
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Argipressin Acetate; Pitressin; Vasopressin. H-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bond)

IUPAC/Chemical Name: (S)-N-((S)-1-((2-amino-2-oxoethyl)amino)-5-guanidino-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide acetate

InChi Key: ZHFGXNMADRRGQP-DIPGXKJRSA-N

InChi Code: InChI=1S/C46H65N15O12S2.C2H4O2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25;1-2(3)4/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53);1H3,(H,3,4)/t27-,28+,29-,30-,31-,32-,33-,34-;/m0./s1

SMILES Code: O=C([C@H]1N(C([C@@H](NC([C@H](CC(N)=O)NC([C@H](CCC(N)=O)NC([C@H](CC2=CC=CC=C2)NC([C@H](CC3=CC=C(O)C=C3)N4)=O)=O)=O)=O)CSSC[C@H](N)C4=O)=O)CCC1)N[C@@H](C(NCC(N)=O)=O)CCCNC(N)=N.CC(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,144.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Cohn JA, Kowalik CG, Reynolds WS, Kaufman MR, Milam DF, Dmochowski RR, Wein AJ. Desmopressin acetate nasal spray for adults with nocturia. Expert Rev Clin Pharmacol. 2017 Dec;10(12):1281-1293. doi: 10.1080/17512433.2017.1394185. Epub 2017 Oct 30. PMID: 29048257.

2: Karanth L, Barua A, Kanagasabai S, Nair S. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Cochrane Database Syst Rev. 2015 Sep 9;(9):CD009824. doi: 10.1002/14651858.CD009824.pub3. Update in: Cochrane Database Syst Rev. 2019 Feb 13;2:CD009824. PMID: 26350784.

3: Karanth L, Barua A, Kanagasabai S, Nair NS. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009824. doi: 10.1002/14651858.CD009824.pub2. Update in: Cochrane Database Syst Rev. 2015;(9):CD009824. PMID: 23633378.

4: Alford N, Hashim H. Desmopressin acetate the first sublingual tablet to treat nocturia due to nocturnal polyuria. Expert Rev Clin Pharmacol. 2021 Aug;14(8):939-954. doi: 10.1080/17512433.2021.1931122. Epub 2021 Jun 14. PMID: 33993824.

5: Ferraris VA, Klingman R, Bufo A, Saifi J. Cardiopulmonary bypass. Curr Opin Cardiol. 1991 Apr;6(2):227-34. doi: 10.1097/00001573-199104000-00009. PMID: 10171173.

6: Hayashi M. [Pharmacological and clinical profile of desmopressin acetate hydrate (MINIRIN Melt(®))]. Nihon Yakurigaku Zasshi. 2013 Mar;141(3):169-74. Japanese. doi: 10.1254/fpj.141.169. PMID: 23470483.

7: Higasa S, Tokugawa T, Sawada A. [Diagnosis and management of von Willebrand disease]. Rinsho Ketsueki. 2018;59(10):2222-2232. Japanese. doi: 10.11406/rinketsu.59.2222. PMID: 30305529.

8: Lim CC, Tan HZ, Tan CS, Healy H, Choo J, Franca Gois PH. Desmopressin acetate to prevent bleeding in percutaneous kidney biopsy: a systematic review. Intern Med J. 2021 Apr;51(4):571-579. doi: 10.1111/imj.14774. PMID: 32040251.

9: Daugirdas JT, Nawab ZM. Acetate relaxation of isolated vascular smooth muscle. Kidney Int. 1987 Jul;32(1):39-46. doi: 10.1038/ki.1987.169. PMID: 3626298.

10: Korkmaz U, Demir E, Yazici H, Sever MS. Hypertensive pulmonary edema related to desmopressin acetate. Nefrologia. 2017 May-Jun;37(3):349-350. English, Spanish. doi: 10.1016/j.nefro.2016.11.008. PMID: 28648214.

11: Daugirdas JT, Swanson V, Islam S, Nutting C, Kim DD, Wang XA, Fiscus RR. Acetate causes endothelium-independent increases in cyclic AMP in rat caudal artery. Am J Physiol. 1988 Dec;255(6 Pt 2):H1378-83. doi: 10.1152/ajpheart.1988.255.6.H1378. PMID: 2462365.

12: McManus J, Ferreira J, Jones GM, Smetana KS, Smith Condeni M, Berger K, Witenko C, Smotherman C, Gautam S, Pizzi MA, Erdman MJ. Effect of desmopressin acetate on acute spontaneous intracranial hemorrhage in patients on antiplatelet therapy. J Neurol Sci. 2022 Mar 15;434:120142. doi: 10.1016/j.jns.2022.120142. Epub 2022 Jan 6. PMID: 35081458.

13: Zachoval R, Krhut J, Šottner O, Hanuš T, Martan A, Horčička L, Feyereisl J, Halaška M, Švabík K, Krofta L. Léčba noční polyurie desmopresinem [Nocturnal polyuria, treatment with desmopressin]. Ceska Gynekol. 2013 Aug;78(4):385-9. Czech. PMID: 24040989.

14: Steele BT. Nocturnal enuresis. Treatment options. Can Fam Physician. 1993 Apr;39:877-80. PMID: 8495145; PMCID: PMC2379840.

15: Vance DA. Desmopressin acetate. J Post Anesth Nurs. 1988 Feb;3(1):65-6. PMID: 3351781.

16: Bloom DA. The American experience with desmopressin. Clin Pediatr (Phila). 1993 Jul;Spec No:28-31. doi: 10.1177/0009922893032001s07. PMID: 8039336.

17: Karanth L, Barua A, Kanagasabai S, Nair NS. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Cochrane Database Syst Rev. 2019 Feb 13;2(2):CD009824. doi: 10.1002/14651858.CD009824.pub4. PMID: 30758840; PMCID: PMC6373982.

18: Qiao LY, Du YC. Involvement of a putative G-protein-coupled receptor and a branching pathway in argipressin (4-8) signal transduction in rat hippocampus. Zhongguo Yao Li Xue Bao. 1998 Jan;19(1):15-20. PMID: 10375750.

19: Moffatt ME, Harlos S, Kirshen AJ, Burd L. Desmopressin acetate and nocturnal enuresis: how much do we know? Pediatrics. 1993 Sep;92(3):420-5. PMID: 8361796.

20: Mansouritorghabeh H, Shirdel A. Desmopressin acetate as a haemostatic elevator in individuals with combined deficiency of factors V and VIII: a clinical trial. J Thromb Haemost. 2016 Feb;14(2):336-9. doi: 10.1111/jth.13207. Epub 2016 Jan 30. PMID: 26599105.

Your view history

Argipressin Acetate featured